Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Fleming

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
The Journal of Orthopaedic and Sports Physical Therapy|May 4, 2010
Asymptomatic spondylolisthesis and pregnancyJames M Elliott, Helen Fleming, Kylie Tucker
Skin Health and Disease|June 30, 2025
Skin cancer screening practices of UK hairdressers and barbers for their customers: a preliminary studyHelen Fleming, Chris Wells, Andrew Williams, et al.
Clinical Toxicology (Philadelphia, Pa.)|June 13, 2015
Estimation of Monocrotophos renal elimination half-life in humansArun Jose, Ratnasamy Selvakumar, John Victor Peter, et al.
Journal of Clinical and Diagnostic Research : JCDR|September 16, 2016
Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation DeliveryPradeep Rajkumar, Binu Susan Mathew, Saikat Das, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 16, 2025
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-studyA Murray Brunt, Fay H Cafferty, Duncan Wheatley, et al.
Health Technology Assessment (Winchester, England)|November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCTAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
The Lancet. Oncology|May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudyAdrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
The Journal of Orthopaedic and Sports Physical Therapy|May 4, 2010
Asymptomatic spondylolisthesis and pregnancyJames M Elliott, Helen Fleming, Kylie Tucker
Skin Health and Disease|June 30, 2025
Skin cancer screening practices of UK hairdressers and barbers for their customers: a preliminary studyHelen Fleming, Chris Wells, Andrew Williams, et al.
Clinical Toxicology (Philadelphia, Pa.)|June 13, 2015
Estimation of Monocrotophos renal elimination half-life in humansArun Jose, Ratnasamy Selvakumar, John Victor Peter, et al.
Journal of Clinical and Diagnostic Research : JCDR|September 16, 2016
Cisplatin Concentrations in Long and Short Duration Infusion: Implications for the Optimal Time of Radiation DeliveryPradeep Rajkumar, Binu Susan Mathew, Saikat Das, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 16, 2025
Patient- and clinician-assessed five-year normal tissue effects following one-week versus three-week axillary radiotherapy for breast cancer: Results from the phase III FAST-Forward trial randomised nodal sub-studyA Murray Brunt, Fay H Cafferty, Duncan Wheatley, et al.
Health Technology Assessment (Winchester, England)|November 22, 2023
One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCTAdrian Murray Brunt, Joanne S Haviland, Duncan A Wheatley, et al.
The Lancet. Oncology|May 14, 2026
Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudyAdrian Murray Brunt, Fay H Cafferty, Anna M Kirby, et al.
Pageof 1